These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8452332)

  • 1. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
    Bakris GL
    Ann Intern Med; 1993 Apr; 118(8):643-4. PubMed ID: 8452332
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibitors and diabetic nephropathy.
    Mogensen CE
    BMJ; 1992 Feb; 304(6823):327-8. PubMed ID: 1540721
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
    Sternlicht H; Bakris GL
    Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy.
    Lewis EJ
    Contrib Nephrol; 1996; 118():206-13. PubMed ID: 8744059
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiotensin-converting enzyme inhibitors in the treatment of diabetic nephropathy].
    Sawicki PT; Mühlhäuser I; Berger M
    Dtsch Med Wochenschr; 1994 Sep; 119(38):1298-9. PubMed ID: 7924925
    [No Abstract]   [Full Text] [Related]  

  • 8. ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group.
    Marre M; Lievre M; Chatellier G; Plouin PF
    Lancet; 1995 Dec; 346(8990):1638. PubMed ID: 7500787
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H; Lazich I; Bakris GL
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personal viewpoint: new developments in the therapy of diabetic hypertensive disease. The ABCD study adds to strong evidence favoring the prime use of ACE inhibitors. Appropriate Blood Pressure Control in Diabetes.
    Opie LH
    Cardiovasc Drugs Ther; 1998 Jul; 12(3):233-8. PubMed ID: 9784901
    [No Abstract]   [Full Text] [Related]  

  • 11. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy: evidence for renoprotection and practice.
    Mogensen CE
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i26-8:discussion i50. PubMed ID: 10956317
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F
    BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ACE inhibition on the course of nephropathy in type I diabetes mellitus.
    Meinders AE; Hes R; de Leeuw PW
    Neth J Med; 1992 Jun; 40(5-6):217-20. PubMed ID: 1436257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.
    Imanishi M; Yoshioka K; Okumura M; Konishi Y; Tanaka S; Fujii S; Kimura G
    Kidney Int Suppl; 1997 Dec; 63():S198-200. PubMed ID: 9407458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy.
    Heinemann L; Janicke I; Bender R; Berger M; Sawicki PT
    Horm Metab Res; 1996 Oct; 28(10):549-52. PubMed ID: 8934214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.